Abstract: A procedure for finding and identifying red cell antibodies by means of the solid-phase method, comprising contacting erythrocytes having selected antigen patterns with sera or plasmas that are to be tested for antibodies and transferred along with a polyspecific anti-human globulin reagent onto a substrate coated with protein A or protein G, thereby to transfer the detection or identification cells or, in the case of autocontrols, inherent cells.

Abstract: A method of, and support and kit for, determining blood groups by the solid-phase procedure with blood-group specific immunoglobulin-M antibodies. The support is prepared by applying to its surface a solution of the immunoglobulin-M antibodies and simultaneously applying to the surface of the support a suspension of erythrocytes that is being tested, or drying the surface of the support to form a ready-to-use reagent, and subsequently contacting the surface with a suspension of erythrocytes, and determining the blood group just after the contact occurs, the concentration of antibodies being just sufficient to create an irreversible or immobilized coating of antibody molecules on the surface that can specifically attach erythrocytes but insufficient to induce an agglutination reaction.

Abstract: A microtiter plate for blood typing consisting of a flat-bottomed plate of rigid transparent polystyrene having a plurality of wells, the polystyrene being surface treated by a corona and/or plasma method of applying high power electric energy at high frequency resulting in a permanently measurable negative ion-charge at the surface of the wells, and layers of substantially pure antiserums dried on the wells without any binder from a suspension or solution of the antiserums and tightly but releasably bound to the polystryene.

Abstract: There are prepared compounds corresponding to the general formula: ##STR1## in which R represents a 2,2-dimethylethenyl; isopropyl; nonyl; a C.sub.3 -C.sub.6 -cycloalkyl radical; a phenyl group substituted by at least one nitro group, or a C.sub.1 -C.sub.6 -alkyl group containing a morpholine group attached thereto, said morpholine ring being substituted zero to twice by C.sub.1 -C.sub.6 -alkyl groups; R.sub.3 is --CHO or --CH.sub.2 OH, their optically active forms and their salts. The compounds have cardioactivity e.g., bradycardic effect and have local anethetic, spasmolytic and antiarythmic activity.

Abstract: Compounds are prepared of the formula ##STR1## The compounds of the invention possess valuable pharmacodynamic properties. They especially have a positive inotropic effect which is particularly noted in oral or enteral application. In contrast to the known compounds the compounds of the invention have more favorable pharmacological or pharmaceutical properties.